Differential association for N-acetyltransferase 2 genotype and phenotype with bladder cancer risk in Chinese population

N-acetyltransferase 2 (NAT2) is involved in both carcinogen detoxification through hepatic N-acetylation and carcinogen activation through local O-acetylation. NAT2 slow acetylation status is significantly associated with increased bladder cancer risk among European populations, but its association...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-06, Vol.7 (26), p.40012-40024
Main Authors: Quan, Lei, Chattopadhyay, Koushik, Nelson, Heather H, Chan, Kenneth K, Xiang, Yong-Bing, Zhang, Wei, Wang, Renwei, Gao, Yu-Tang, Yuan, Jian-Min
Format: Article
Language:English
Subjects:
Aged
Arylamine N-Acetyltransferase - genetics
Asian People
Caffeine - metabolism
Carcinogens - metabolism
Case-Control Studies
China
Female
Gene Expression Regulation, Neoplastic
Genetic Predisposition to Disease
Genotype
Humans
Male
Middle Aged
Odds Ratio
Phenotype
Polymorphism, Single Nucleotide
Research Paper
Risk
Urinary Bladder Neoplasms - ethnology
Urinary Bladder Neoplasms - genetics
Urinary Bladder Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:N-acetyltransferase 2 (NAT2) is involved in both carcinogen detoxification through hepatic N-acetylation and carcinogen activation through local O-acetylation. NAT2 slow acetylation status is significantly associated with increased bladder cancer risk among European populations, but its association in Asian populations is inconclusive. NAT2 acetylation status was determined by both single nucleotide polymorphisms (SNPs) and caffeine metabolic ratio (CMR), in a population-based study of 494 bladder cancer patients and 507 control subjects in Shanghai, China. The CMR, a functional measure of hepatic N-acetylation, was significantly reduced in a dose-dependent manner among both cases and controls possessing the SNP-inferred NAT2 slow acetylation status (all P-values
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.9475